13,409
edits
Vaccination
(From Wikipedia.org) |
(Vaccination) |
||
| Line 148: | Line 148: | ||
On 23 April 2021, [[Cadila Healthcare]] received an emergency authorisation to repurpose [[Peginterferon alfa-2b]], a medication used to treat [[hepatitis C]], as a treatment for moderate COVID-19 in adults.<ref>{{Cite web|date=2021-04-23|title=India's Cadila gets approval to repurpose Hepatitis C drug for Covid-19|url=https://www.hindustantimes.com/india-news/indias-cadila-gets-approval-to-repurpose-hepatitis-c-drug-for-covid19-101619171912735.html|access-date=2021-04-24|website=Hindustan Times|language=en}}</ref> | On 23 April 2021, [[Cadila Healthcare]] received an emergency authorisation to repurpose [[Peginterferon alfa-2b]], a medication used to treat [[hepatitis C]], as a treatment for moderate COVID-19 in adults.<ref>{{Cite web|date=2021-04-23|title=India's Cadila gets approval to repurpose Hepatitis C drug for Covid-19|url=https://www.hindustantimes.com/india-news/indias-cadila-gets-approval-to-repurpose-hepatitis-c-drug-for-covid19-101619171912735.html|access-date=2021-04-24|website=Hindustan Times|language=en}}</ref> | ||
===Vaccination === | |||
{{main|COVID-19 vaccination in India}} | |||
[[File:The Union Minister for Health & Family Welfare, Science & Technology and Earth Sciences, Dr. Harsh Vardhan visiting the GTB Hospital, Shahdara to review the preparedness of Dry Run of COVID-19 vaccine, in Delhi on January 02, 2021 (2).jpg|thumb|Union Minister for Health & Family Welfare, [[Harsh Vardhan (Delhi politician)|Dr. Harsh Vardhan]] visiting the GTB Hospital, Shahdara to review the preparedness of Dry Run of COVID-19 vaccine, in Delhi on 2 January 2021.]] | |||
In September 2020, federal science minister [[Harsh Vardhan (Delhi politician)|Harsh Vardhan]] stated that the country planned to have a [[COVID-19 vaccine]] approved within the first quarter of 2021.<ref>{{Cite news|title=Expect Covid-19 vaccine by early next year, will take first shot if any trust deficit: Vardhan|url=https://m.timesofindia.com/india/covid-vaccine-likely-by-early-2021-for-old-high-risk-first-harsh-vardhan/articleshow/78091084.cms|newspaper=The Times of India|date=2020-09-13|access-date=2020-09-13}}</ref> 30 million health workers directly dealing with COVID patients, especially doctors and other medical personnel, were to be prioritised as part of Phase 1.<ref>{{Cite news|location=New Delhi|last=Kaul|first=Rhythma|title=30 Million Frontline Workers To Get Covid-19 Vaccine In Phase 1|url=https://m.hindustantimes.com/india-news/30-million-frontline-workers-to-get-covid-19-vaccine-in-phase-1/story-W76e1pJ7toA4aod3hH234O.html|newspaper=Hindustan Times|date=2020-10-21|access-date=2020-10-21}}</ref> | |||
On 1 January 2021, the [[Drug Controller General of India]] granted an emergency use authorisation to the British [[Oxford–AstraZeneca COVID-19 vaccine|Oxford–AstraZeneca vaccine]], which is being produced locally by the [[Serum Institute of India]] under the trade name "Covishield" for domestic use and export.<ref>{{Cite news|others=PTI|date=2020-12-28|title=Already produced 40-50 million dosages of Covishield vaccine, says Serum Institute|language=en-IN|work=The Hindu|url=https://www.thehindu.com/business/Industry/already-produced-40-50-million-dosages-of-covishield-vaccine-says-serum-institute/article33438655.ece|access-date=2021-04-26|issn=0971-751X}}</ref><ref>{{Cite news|last=Schmall|first=Emily|last2=Yasir|first2=Sameer|date=2021-01-03|title=India Approves Oxford-AstraZeneca Covid-19 Vaccine and 1 Other|language=en-US|work=The New York Times|url=https://www.nytimes.com/2021/01/03/world/asia/india-covid-19-vaccine.html|access-date=2021-04-22|issn=0362-4331}}</ref><ref>{{Cite news|date=2021-01-03|title=Coronavirus: India approves vaccines from Bharat Biotech and Oxford/AstraZeneca|language=en-GB|work=BBC News|url=https://www.bbc.com/news/world-asia-india-55520658|access-date=2021-04-22}}</ref><ref name=":16" /><ref>{{Cite news|date=2021-04-06|title=Why is the EU unhappy with AstraZeneca?|language=en-GB|work=BBC News|url=https://www.bbc.com/news/56483766|access-date=2021-04-22}}</ref> | |||
On 2 January, the country also approved [[BBV152]] (Covaxin), a domestic vaccine developed by [[Bharat Biotech]] in association with the [[Indian Council of Medical Research]] and [[National Institute of Virology]].<ref>{{cite news|date=2 January 2021|title=Expert panel recommends Bharat Biotech's Covaxin for restricted emergency use|publisher=News18|url=https://www.news18.com/news/india/expert-panel-clears-bharat-biotechs-covaxin-amid-uk-virus-strain-what-you-need-to-know-3240500.html|access-date=2 January 2021}}</ref> This approval was met with some concern, as the vaccine had not then completed phase 3 trials.<ref>{{Cite news|last=Prasad|first=R|date=2020-01-15|title=Vaccine dilemma — to take or not to take Covaxin|newspaper=The Hindu|location=Chennai|url=https://www.thehindu.com/sci-tech/health/vaccine-dilemma-to-take-or-not-to-take-covaxin/article33577223.ecel|access-date=2020-01-16}}</ref> | |||
India officially launched its vaccination program on 16 January, Over {{Lakh|1.6}} doses were administered on the first day.<ref>{{Cite web|date=2021-01-16|title=Covid-19 vaccination in India Day 1: Over 1.9 lakh people inoculated, says govt|url=https://www.livemint.com/news/india/covid19-vaccination-in-india-day-1-over-1-6-lakh-people-inoculated-3-351-sessions-held-says-govt-11610804057599.html|access-date=2021-04-23|website=mint|language=en}}</ref> | |||
Due to the second wave, in late-March 2021 the country placed a hold on all exports of the AstraZeneca vaccine in order to meet local demand.<ref name=":16" /> In April 2021, India approved the Russian [[Sputnik V COVID-19 vaccine|Sputnik V]] vaccine.<ref name=":13" /> | |||
==See also== | ==See also== | ||